Bonus Biogroup

Bonus Biogroup Current Liabilities

The Current Liabilities of Bonus Biogroup (BONS.TA) as of Nov 1, 2026 is 13.99 M ILS. In the previous year, Current Liabilities was 9.58 M ILS — a change of 46.15% (higher).

Current Liabilities

13.99 MILS

YoY

46.15%

Last updated:

Current Liabilities of Bonus Biogroup is 2025 13.99 M ILS. Current Liabilities of Bonus Biogroup was 2024 9.58 M ILS. It decreases by 46.15% higher compared to the previous year.

The Bonus Biogroup Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
3.08 M ILS
Jan 1, 2019
4.86 M ILS
Jan 1, 2020
3.79 M ILS
Jan 1, 2021
3.75 M ILS
Jan 1, 2022
4.41 M ILS
Jan 1, 2023
7.39 M ILS
Jan 1, 2024
9.58 M ILS
Jan 1, 2025
13.99 M ILS
The Bonus Biogroup Current Liabilities history
YEARCurrent LiabilitiesYoY
13.99 MILS+46.15%
9.58 MILS+29.50%
7.39 MILS+67.66%
4.41 MILS+17.71%
3.75 MILS-1.24%
3.79 MILS-21.90%
4.86 MILS+57.79%
3.08 MILS-18.14%
3.76 MILS-63.34%
10.26 MILS+43.58%
7.15 MILS+82.32%
3.92 MILS+63.84%
2.39 MILS+29.23%
1.85 MILS+107.74%
891,000.00ILS-97.61%
37.25 MILS-27.71%
51.53 MILS+58.66%
32.48 MILS+0.80%
32.22 MILS+22.98%
26.20 MILS-22.37%
33.75 MILS+21.67%
27.74 MILS-25.21%
37.09 MILS+15.55%
32.10 MILS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bonus Biogroup Stock analysis

What does Bonus Biogroup do? The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bonus Biogroup stock

Current Liabilities of Bonus Biogroup is 13.99 M ILS in 2025.

Current Liabilities of Bonus Biogroup changed from 9.58 M ILS to 13.99 M ILS, representing a 46.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Bonus Biogroup since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's ILS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Bonus Biogroup historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bonus Biogroup

All Key Metrics — Bonus Biogroup